NETRF played a meaningful and visible role at the 14th Annual European Neuroendocrine Tumor Society (ENETS) Conference, March 8-10, 2017, in Barcelona, Spain. Our U.S. contingent participated at the podium, in panels, and focused discussions to strengthen ties worldwide in the search for scientific advances in NETs.
NETRF joins hands with international counterparts
NETRF leadership crossed the Atlantic to the ENETS conference to strengthen international partnerships. Executive staff, board members, scientific advisors, and researchers shared the organization’s goals, interests, and needs with an international audience.
“Continents should not separate the NET community. We have similar interests and shared challenges,” said Ron Hollander, NETRF executive director. “Collaboration can promote the exchange of ideas, knowledge, and technology.”
Recapping ENETS 2017
ENETS is comprised of Europe’s top physicians and scientists dedicated to the treatment of neuroendocrine tumors and carcinoma. The four days of meetings with more than 1,500 participants featured posters and presentations from over 350 clinicians and researchers on clinical, translational, and basic research.
The conference featured a long-awaited update from Dr. James C. Yao, The University of Texas MD Anderson Cancer Center, on his seminal 2008 article on the demographics of NETs. His latest study suggests increases in prevalence and improved longevity for NET patients in America. Yao’s paper, soon to be published by JAMA Oncology, will be a pivotal platform upon which to discuss the burden of NETs in the U.S. Watch NETRF’s E-Update for news and information on this research.
An interesting session focused on the immune system, the lack of clinical response in NETs to vaccines, and lessons learned from other cancers. Matthew H. Kulke, MD, Harvard Medical School, a NETRF-funded investigator, discussed his work on the roles of proteins (i.e., PD-1, PDL-1, and PDL-2) that are often overexpressed in NETs and cause local immune suppression.
Other highlights of the meeting included discussions on medical therapies for carcinoid syndrome and lung NETs, up-to-date information on clinical and surgical trials, and a lecture on the challenges in using the current tumor classification system.
The final day of the ENETS Conference featured the first-ever joint symposium with the International Neuroendocrine Cancer Alliance (INCA), co-chaired by Ron Hollander who serves as NETRF executive director and INCA president, and Massimo Falconi, MD, chairman ENETs. For information on the symposium, read MORE.